摘要
目的观察分析采用酪酸梭菌肠球菌三联活菌片联合蒙脱石散(思密达)治疗小儿肺炎继发性腹泻的临床治疗效果。方法 220例小儿肺炎继发性腹泻患儿作为研究对象,随机分为调节止泻组和单一止泻组,各110例。单一止泻组给予思密达治疗;调节止泻组给予酪酸梭菌肠球菌三联活菌片联合思密达治疗。治疗3 d后分别记录两组患儿临床治疗效果,并比较。结果单一止泻组总有效率为97.27%,调节止泻组总有效率为82.73%,调节止泻组总有效率明显优于单一止泻组,差异具有统计学意义(P<0.05)。结论酪酸梭菌肠球菌三联活菌片联合思密达治疗小儿肺炎继发性腹泻效果明显,值得临床广泛应用。
ObjectiveTo observe and analyze clinical effect by clostridium butyricum enterococcus triple viable tablets combined with Montmorillonite powder （Smecta） in the treatment of pediatric pneumonia secondary diarrhea.MethodsA total of 220 children patients with pneumonia secondary diarrhea as study subjects were randomly divided into adjusted antidiarrheal group and single antidiarrheal group, with 110 cases in each group. The single antidiarrheal group received Smecta for treatment, and the adjusted antidiarrheal group received clostridium butyricum enterococcus triple viable tablets combined with Smecta for treatment. Clinical effects of the two groups were recorded after 3 d of treatment for comparison.ResultsThe single antidiarrheal group had total effective rate as 97.27%, and that of the adjusted antidiarrheal group was 82.73%. The adjusted antidiarrheal group had much better total effective rate than the single antidiarrheal group, and their difference had statistical significance （P〈0.05）.ConclusionCombination of clostridium butyricum enterococcus triple viable tablets and Smecta provides precise effect in treating pediatric pneumonia secondary diarrhea, and it is worthy of widely clinical application.
出处
《中国现代药物应用》
2015年第21期23-24,共2页
Chinese Journal of Modern Drug Application
关键词
酪酸梭菌肠球菌三联活菌片
思密达
小儿肺炎继发性腹泻
Clostridium butyricum enterococcus triple viable tablets
Smecta
Pediatric pneumonia secondary diarrhea
